STEVEN MCCULLOUGH: Open Payments
NPI 1992791925 · PANDORA, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,400 in 118 payments from 23 companies in 2025. Trend: 2023 $2,195 · 2024 $2,614 · 2025 $2,400
Food & beverage: $2,400
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 15 | $408 |
| Lilly USA, LLC | 15 | $385 |
| ABBVIE INC. | 21 | $315 |
| Novo Nordisk Inc | 16 | $208 |
| Otsuka America Pharmaceutical, Inc. | 10 | $179 |
| Kowa Pharmaceuticals America, Inc. | 7 | $168 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $149 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $138 |
| Abbott Laboratories | 4 | $76 |
| Boston Scientific Corporation | 2 | $62 |
Products named: AIRSUPRA, MOUNJARO, REXULTI, ZORYVE, XIFAXAN, VRAYLAR, CAPLYTA, ZEPBOUND.
Industry payments across OH — which companies pay providers there.
